文献速递肝病

代谢生物标志物显著提升HBV相关慢加急性肝衰竭发生与结局的预测

Metabolic biomarkers significantly enhance the prediction of HBV-related ACLF occurrence and outcomes.
PubMed 文献 · J Hepatol · 2023-07-29

多中心前瞻性研究对1024例HBV相关慢性肝病急性加重患者入院血浆行代谢组学分析,随机分为发现集与验证集,构建预测ACLF患者90天死亡及非ACLF患者28天内进展为ACLF的算法,发现集AUC分别为0.87和0.94,验证集分别为0.83和0.88。

要点

  • ACLF显著改变血浆代谢组,涉及膜脂代谢、类固醇激素、氧化应激和能量代谢通路。
  • 基于代谢标志物的算法预测ACLF患者90天死亡,发现集AUC 0.87、验证集0.83。
  • 诊断pre-ACLF的算法发现集AUC 0.94、验证集0.88,并开发了液相色谱-质谱靶向检测。

核心结论

  • 基于新型代谢物标志物建立的HBV相关ACLF检测方法,准确性高于现有方法。

研究设计与样本

  • 多年度多中心前瞻性研究,纳入1024例HBV相关慢性肝病急性加重患者入院血浆样本,其中ACLF 367例、非ACLF 657例。
  • 样本随机等分为发现集和验证集,用统计分析和机器学习鉴定标志物并开发算法。

主要发现

  • ACLF显著改变血浆代谢组,尤其涉及膜脂代谢、类固醇激素、氧化应激通路和能量代谢。
  • 预测ACLF患者90天死亡的AUC在发现集为0.87、验证集为0.83。
  • 诊断pre-ACLF的AUC在发现集为0.94、验证集为0.88。

关键数值与推荐

  • 预测ACLF患者90天死亡:发现集AUC 0.87,验证集AUC 0.83。
  • 诊断pre-ACLF(非ACLF组28天内进展为ACLF):发现集AUC 0.94,验证集AUC 0.88。
  • 临床试验注册号:NCT02457637和NCT03641872。

临床怎么用

  • 作者基于新型代谢物标志物开发了液相色谱-质谱检测,称其可在临床实验室实施并用于HBV相关ACLF患者分诊以优化临床管理。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Acute-on-chronic liver failure (ACLF) is a clinical syndrome associated with high short-term mortality in patients with chronic liver disease. Chronic hepatitis B is the main cause of ACLF (HBV-ACLF) in China and other Asian countries. To improve disease management and survival for patients with ACLF, we aimed to discover novel biomarkers to enhance HBV-ACLF diagnosis and prognostication. METHODS: We performed a metabolomics profiling of 1,024 plasma samples collected from patients with HBV-related chronic liver disease with acute exacerbation at hospital admission in a multi-year and multi-center prospective study (367 ACLF and 657 non-ACLF). The samples were randomly separated into equal halves as a discovery set and a validation set. We identified metabolites associated with 90-day mortality in the ACLF group and the progression to ACLF within 28 days in the non-ACLF group (pre-ACLF) using statistical analysis and machine learning. We developed diagnostic algorithms in the discovery set and used these to assess the findings in the validation set. RESULTS: ACLF significantly altered the plasma metabolome, particularly in membrane lipid metabolism, steroid hormones, oxidative stress pathways, and energy metabolism. Numerous metabolites were significantly associated with 90-day mortality in the ACLF group and/or pre-ACLF in the non-ACLF group. We developed algorithms for the prediction of 90-day mortality in patients with ACLF (area under the curve 0.87 and 0.83 for the discovery set and validation set, respectively) and the diagnosis of pre-ACLF (area under the curve 0.94 and 0.88 for the discovery set and validation set, respectively). To translate our discoveries into practical clinical tests, we developed targeted assays using liquid chromatography-mass spectrometry. CONCLUSIONS: Based on novel metabolite biomarkers, we established tests for HBV-related ACLF with higher accuracy than existing methods. CLINICAL TRIAL NUMBER: NCT02457637 and NCT03641872. IMPACT AND IMPLICATIONS: Acute-on-chronic liver failure (ACLF) is a clinical syndrome associated with high short-term mortality affecting 25% of patients hospitalized with cirrhosis. Chronic hepatitis B is the main etiology of ACLF in China and other Asian counties. There is currently no effective therapy. Early diagnosis and accurate prognostication are critical for improving clinical outcomes in patients with ACLF. Based on novel metabolite biomarkers, we developed liquid chromatography-mass spectrometry tests with improved accuracy for the early diagnosis and prognostication of HBV-related ACLF. The liquid chromatography-mass spectrometry tests can be implemented in clinical labs and used by physicians to triage patients with HBV-related ACLF to ensure optimized clinical management.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Zhang Y, Tan W, Wang X, et al. Metabolic biomarkers significantly enhance the prediction of HBV-related ACLF occurrence and outcomes. J Hepatol. 2023. PMID: 37517452. doi:10.1016/j.jhep.2023.07.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。